Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021206636 - ANTIGEN-BINDING PROTEIN TO SARS-CoV-2

Publication Number WO/2021/206636
Publication Date 14.10.2021
International Application No. PCT/SG2021/050195
International Filing Date 07.04.2021
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61K 39/42 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
G01N 33/53 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/55
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
55Fab or Fab'
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K 2317/92
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
90characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applicants
  • AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG]/[SG]
Inventors
  • WANG, Cheng-I
  • WANG, Bei
  • NGOH, Zi Xian Eve
  • LEE, Wen-Hsin
  • HU, Yuanyu
  • LEE, Chia Yin
  • TAN, Hwee Ching
  • NG, Patricia Miang Lon
  • MINHAT, Rabiatul Adawiyah Binte
  • HUANG, Ching-Wen
  • SOH, Mun Kuen
  • YEAP, Yee Chin, Yvonne
  • TEO, Jiuyi Frannie
Agents
  • DONALDSON & BURKINSHAW LLP
Priority Data
10202003204P07.04.2020SG
10202004828Q22.05.2020SG
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTIGEN-BINDING PROTEIN TO SARS-CoV-2
(FR) PROTÉINE DE LIAISON À L'ANTIGÈNE DIRIGÉE CONTRE SARS-COV-2
Abstract
(EN) The present invention relates to provide antigen-binding proteins that are capable of binding to and/or neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In one embodiment, the antigen-binding proteins are capable of binding to a spike protein of SARS-CoV-2 including receptor-binding domain (RBD) of SARS-CoV-2. The present invention also provides products comprising the same and methods of using the same for the treatment of SARS-CoV-2 infection or for detecting the presence of SARS-CoV-2 in a sample.
(FR) La présente invention concerne des protéines de liaison à l'antigène qui sont capables de se lier à et/ou de neutraliser un coronavirus 2 du syndrome respiratoire aigu sévère (SRAS-CoV-2). Dans un mode de réalisation, les protéines de liaison à l'antigène sont capables de se lier à une protéine de spicule du SARS-CoV-2 comprenant le domaine de liaison au récepteur (RBD) du SARS-CoV-2. La présente invention concerne également des produits les comprenant et des procédés d'utilisation de ceux-ci pour le traitement d'une infection par le SARS-CoV-2 ou pour la détection de la présence de SARS-CoV-2 dans un échantillon.
Latest bibliographic data on file with the International Bureau